Deals
Biogen Drops $5.6B for Apellis at 140% Premium, Shares Fall
Biogen acquires Apellis for $5.6B at a near 140% premium, adding Syfovre and Empaveli to offset a fading MS franchise ahead of pharma's patent cliff.
Latest — Page 43
FDA
FDA Clears Novocure's Pancreatic Cancer Device in First-Ever Approval
FDA approved Novocure's Optune Pax for locally advanced pancreatic cancer, the first device cleared for it, adding ~2 months to survival over standard chemo.
FDA
FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint
FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.
fda
FDA
Lilly's Oral GLP-1 Pill Cleared in 50 Days, Fastest NME Since 2002
Eli Lilly's oral GLP-1 pill orforglipron approved in 50 days under the FDA's CNPV pilot — the fastest new molecular entity approval since 2002.
FDA
Trump's 100% Pharma Tariff: Who Pays, Who Gets Out
Trump's 100% tariff on branded pharma imports creates a hard deadline: cut MFN pricing deals and reshore, or face full tariffs by 2030.
You've reached the end of the archive.
Want the next stories in your inbox? Subscribe to the newsletter